Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Platform Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

NCT06445062 is registered in ClinicalTrials.gov with Revolution Medicines, Inc. as lead sponsor.

NCT NCT06445062
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06445062 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Platform Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Lead sponsor
Revolution Medicines, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 24, 2024
Completion date
March 30, 2030
Enrollment
1,130 (estimated)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, crc, gastrointestinal cancer, metastatic pancreatic ductal adenocarcinoma, pancreatic ductal adenocarcinoma, pdac